Why Is Geron (GERN) Stock Up 18% Today?

Geron (NASDAQ:GERN) stock is heading higher on Friday after getting approval from the Food and Drug Administration (FDA) for RYTELO. Rami Komrokji, MD, an investigator in the RYTELO clinical trials, said the following about the approval. How This Affects GERN Stock GERN stock is up 18.4% as of Friday morning and is up 114.9% since the start of the year. We have all of the hottest stock market news traders need to know about on Friday. A few examples include what's happening with shares of Apple (NASDAQ:AAPL ...